Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—12/ 14/20-01/18/21

Tom T. Shimabukuro, MD, MPH, MBA1; Matthew Cole, MPH2; John R. Su, MD, PhD, MPH1

JAMA. Published online February 12, 2021. doi:10.1001/jama.2021.1967

In December 2020, the US Food and Drug Administration (FDA) issued Emergency Use Authorizations for 2 mRNA-based vaccines for prevention of coronavirus disease 2019 (COVID-19): Pfizer-BioNTech COVID-19 vaccine (EUA issued December 11; 2 doses, 3 weeks apart) and Moderna COVID-19 vaccine (EUA issued December 18; 2 doses, 1 month apart). Shortly after each authorization, the Advisory Committee on Immunization Practices issued interim recommendations for use.1,2

Read more here : https://jamanetwork.com/journals/jama/fullarticle/2776557?utm_source=silverchair&utm_campaign=jama_network&utm_content=covid_weekly_highlights&utm_medium=email